Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET)
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia
A CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting
Event Details
2:45 PM – 3:15 PM — Registration
and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California
Meeting Room
Seaport A-D (Second Level)
Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine
Member, Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Richard M Stone, MD
Lunder Family Chair in Leukemia
Chief of Staff
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Eunice S Wang, MD
Chief, Leukemia/Benign Hematology Service
Professor of Oncology, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Andrew H Wei, MBBS, PhD
Professor, Department of Haematology
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
University of Melbourne
Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia
Moderator
Eytan M Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development
in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
This activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
Agenda
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting
MODULE 1: Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei
- Factors influencing the selection of treatment for newly diagnosed AML, such as patient age, performance status, medical history and cytogenetic risk profile
- Long-term efficacy data with venetoclax-based combination therapy for older patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy
- Optimal integration of venetoclax-based regimens into the care of older or unfit patients with newly diagnosed AML
- Spectrum, frequency and severity of adverse events associated with venetoclax for AML; optimal monitoring and management protocols
- Published efficacy and safety findings from the Phase III ASCERTAIN AML study assessing oral decitabine/cedazuridine for patients with AML
- Potential role of decitabine/cedazuridine opposite standard hypomethylating agents, including as a component of all-oral up-front therapy
MODULE 2: Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML (sAML) — Dr Stone
- Outcomes observed with standard intensive chemotherapy regimens for younger patients with AML with unfavorable prognostic features, such as complex karyotype and TP53 mutations
- Available findings with and ongoing investigation of venetoclax-based regimens for younger, fit patients with newly diagnosed AML
- Long-term follow-up with CPX-351 for previously untreated sAML; appropriate identification of candidates for this strategy
- Tolerability considerations with CPX-351
- Early data with and ongoing evaluation of CPX-351 for primary AML, alone or combined with other agents
MODULE 3: Role of FLT3 Inhibitors in AML Management — Dr Perl
- Pharmacologic similarities and differences among available FLT3 inhibitors for AML; implications for potency, activity and tolerability
- Principal findings from the Phase III QuANTUM-First study evaluating the addition of quizartinib to chemotherapy and its continuation as a single agent for patients with newly diagnosed AML with a FLT3-ITD mutation
- FDA approval of quizartinib for previously untreated AML with a FLT3-ITD mutation; current clinical role
- Long-term outcomes reported with gilteritinib versus salvage chemotherapy for patients with relapsed/refractory (R/R) AML with a FLT3 mutation; optimal integration into routine practice
- Principal findings from the Phase III BMT CTN 1506/MORPHO study of gilteritinib as post-transplant maintenance for AML with a FLT3-ITD mutation; effect of measurable residual disease status on outcomes
- Early data with gilteritinib combined with standard intensive chemotherapy or venetoclax-based therapy for AML with a FLT3 mutation
- Available data with and ongoing investigations of other novel FLT3 inhibitors, such as crenolanib and BMF-500, for AML with a FLT3 mutation
MODULE 4: Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein
- Mechanistic similarities and differences between available IDH1 inhibitors, such as ivosidenib and olutasidenib, and IDH2 inhibitors, such as enasidenib
- Optimal integration of ivosidenib into treatment for patients with newly diagnosed and R/R AML with an IDH1 mutation
- Major efficacy and safety findings with olutasidenib for R/R AML with an IDH1 mutation
- FDA approval of olutasidenib and optimal integration into management algorithms
- Long-term data supporting the use of enasidenib for R/R AML with an IDH2 mutation; early data and ongoing evaluation in patients with newly diagnosed disease
MODULE 5: Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang
- Mechanism of action of menin inhibitors and rationale for their activity in AML with KMT2A rearrangements and NPM1 mutations
- Pharmacologic similarities and differences among various menin inhibitors under investigation for AML, such as revumenib, ziftomenib and BMF-219
- Early efficacy and safety data with novel menin inhibitors for R/R AML
- Design, eligibility criteria and available efficacy and safety findings from the pivotal Phase II AUGMENT-101 trial evaluating revumenib for patients with R/R acute leukemias; efficacy of revumenib for AML with a KMT2A rearrangement
- FDA approval of revumenib for R/R acute leukemia with a KMT2A translocation and FDA breakthrough therapy designation for ziftomenib for R/R AML with an NPM1 mutation; current and future roles of these agents in clinical practice
- Rationale for targeting CD123 in AML; mechanism of action of the anti-CD123 antibody-drug conjugate pivekimab sunirine
- Available data with, ongoing evaluation of and potential clinical role of pivekimab sunirine for patients with AML
- Other promising novel agents and strategies for patients with AML
CE Information
Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).
Learning Objectives
Upon completion of this activity, participants should be able to
- Recall emerging research data affecting the clinical management of various forms of AML, and as applicable, adapt treatment algorithms based on these findings.
- Analyze patient-specific factors and available trial data guiding the selection of induction therapy for primary and secondary AML to optimize clinical and quality-of-life outcomes.
- Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current and future role of this strategy in clinical care.
- Reflect on available research with approved FLT3 inhibitors, and use this information to guide the clinical management of newly diagnosed or progressive AML harboring a FLT3 mutation.
- Understand published data with and the role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into management algorithms.
- Recognize the scientific justification for the development of menin inhibitors for certain genetically defined subsets of AML, and consider available research findings with and the current and future role of these novel agents.
- Recollect the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel agents and approaches for AML, and appropriately counsel patients about the potential benefits of participation.
CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Perl — Advisory Committees: Aptose Biosciences, Astellas, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Rigel Pharmaceuticals Inc, Schrödinger, Syndax Pharmaceuticals; Consulting Agreements: Astellas, Daiichi Sankyo Inc, Foghorn Therapeutics; Contracted Research: Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: Foghorn Therapeutics; Nonrelevant Financial Relationships: Beat AML LLC, Leukemia & Lymphoma Society. Dr Stone — Consulting Agreements: AbbVie Inc, Amgen Inc, Aptevo Therapeutics, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Cellarity, CTI BioPharma, a Sobi Company, Curis Inc, Daiichi Sankyo Inc, Ensem Therapeutics, GlycoMimetics Inc, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, LAVA Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Aptevo Therapeutics, Ipsen Biopharmaceuticals Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc. Dr Wang — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreement: Kura Oncology; Contracted Research: Arog Pharmaceuticals Inc, Astellas, Biomea Fusion, Cellectis, ImmunoGen Inc, Kura Oncology, Pfizer Inc, Precigen Inc, Sumitomo Dainippon Pharma Oncology Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Daiichi Sankyo Inc, DAVA Oncology, Pfizer Inc; Nonrelevant Financial Relationship: UptoDate (section editor). Prof Wei — Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Consulting Agreements: AbbVie Inc, Aculeus Therapeutics, Novartis, Servier Pharmaceuticals LLC, Shoreline Biosciences; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: HOVON; Speakers Bureaus: AbbVie Inc, Astellas, Bristol Myers Squibb, Novartis, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Prof Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei receives such a financial benefit.
MODERATOR — Dr Stein — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Syndax Pharmaceuticals.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Meeting Room
Seaport A-D (Second Level)
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
Manchester Grand Hyatt is conveniently located 10 minutes (0.5 mile) walking distance from the San Diego Convention Center, where the 66th ASH Annual Meeting is taking place.
If you have any questions, please feel free to contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting and Exposition.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.